IL133011A0 - Method for the production of non-group c adenoviral vectors - Google Patents

Method for the production of non-group c adenoviral vectors

Info

Publication number
IL133011A0
IL133011A0 IL13301198A IL13301198A IL133011A0 IL 133011 A0 IL133011 A0 IL 133011A0 IL 13301198 A IL13301198 A IL 13301198A IL 13301198 A IL13301198 A IL 13301198A IL 133011 A0 IL133011 A0 IL 133011A0
Authority
IL
Israel
Prior art keywords
adenovirus
production
group
adenoviral vectors
producing
Prior art date
Application number
IL13301198A
Other languages
English (en)
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of IL133011A0 publication Critical patent/IL133011A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL13301198A 1997-05-22 1998-05-20 Method for the production of non-group c adenoviral vectors IL133011A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/861,773 US5849561A (en) 1997-05-22 1997-05-22 Method for the production of non-group C adenoviral vectors
PCT/US1998/010367 WO1998053087A1 (fr) 1997-05-22 1998-05-20 Procede de production de vecteurs adenoviraux n'appartenant pas au groupe c

Publications (1)

Publication Number Publication Date
IL133011A0 true IL133011A0 (en) 2001-03-19

Family

ID=25336722

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13301198A IL133011A0 (en) 1997-05-22 1998-05-20 Method for the production of non-group c adenoviral vectors

Country Status (15)

Country Link
US (1) US5849561A (fr)
EP (1) EP0988389B1 (fr)
JP (1) JP2001527420A (fr)
AT (1) ATE325885T1 (fr)
AU (1) AU743923B2 (fr)
BR (1) BR9809846A (fr)
CA (1) CA2289611C (fr)
DE (1) DE69834489T2 (fr)
HU (1) HUP0003331A3 (fr)
IL (1) IL133011A0 (fr)
MX (1) MXPA99010787A (fr)
NZ (1) NZ500920A (fr)
PL (1) PL336941A1 (fr)
SK (1) SK156799A3 (fr)
WO (1) WO1998053087A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
IL122614A0 (en) * 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
WO2000012740A2 (fr) 1998-08-28 2000-03-09 Duke University ADENOVIRUS A DELETIONS DANS LES SEQUENCES IVa2, 100K ET/OU DE PROTEINES PRETERMINALES
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU768836B2 (en) * 1999-04-06 2004-01-08 Advec, Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1170363B1 (fr) * 2000-02-02 2007-11-21 Kaneda, Yasufumi Vecteur d'enveloppe virale pour transfert de gene
EP1157999A1 (fr) * 2000-05-24 2001-11-28 Introgene B.V. Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci
WO2002024730A2 (fr) * 2000-09-20 2002-03-28 Crucell Holland B.V. Vecteurs de transfert de genes munis d'un tropisme tissulaire pour des cellules dendritiques
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2003020893A2 (fr) * 2001-08-30 2003-03-13 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nouveaux vecteurs d'adenovirus type 7
AU2003225589A1 (en) 2002-02-22 2003-09-09 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Brother of the regulator of imprinted sites (boris)
ES2335657T3 (es) * 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
JP4237449B2 (ja) 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
AU2003268145A1 (en) * 2002-08-22 2004-03-11 Merck And Co., Inc. Methods for propagating adenovirus and virus produced thereby
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
EP1606397A1 (fr) * 2003-03-17 2005-12-21 Merck & Co., Inc. Vecteurs adenoviraux de serotype 24, acides nucleiques et virus produits par ceux-ci
EP1649028B1 (fr) * 2003-07-25 2012-08-22 Genvec, Inc. Vaccins a base de vecteurs adenoviraux
EP1687032B1 (fr) 2003-11-14 2010-02-24 Genvec, Inc. Composition thérapeutique pour le traitement du cancer pancréatique local avancé (lapc).
CA2880061C (fr) 2004-01-23 2018-03-13 Agostino Cirillo Porteurs de vaccin adenoviral de chimpanze
CA2563396A1 (fr) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methode pour utiliser les vecteurs adenovirals amener une reponse immunitaire
WO2006039045A2 (fr) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methode d'utilisation de vecteurs adenoviraux presentant une immunogenicite accrue in vivo
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
US20080248060A1 (en) * 2007-01-09 2008-10-09 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2009149252A1 (fr) * 2008-06-04 2009-12-10 Cornell University Vaccins pour la prévention et le traitement d’une dépendance
WO2011047316A1 (fr) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Séquences d'acides nucléiques codant pour des protéines mosaïques extensibles du vih
CN102892429B (zh) 2010-03-17 2016-08-31 康奈尔大学 基于被破坏的腺病毒的抗滥用药物疫苗
WO2012083297A2 (fr) 2010-12-17 2012-06-21 Genvec, Inc. Vecteurs adénoviraux avec régions d'hexon modifiées
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
WO2012162428A1 (fr) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Primovaccination-rappel pour infection virale
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
EP2855511B1 (fr) 2012-05-29 2019-07-24 GenVec, Inc. Vaccin contre le virus de l'herpes simplex
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
WO2018176103A1 (fr) 2017-03-30 2018-10-04 The University Of Queensland Molécules chimériques et utilisations associées
CA3062591A1 (fr) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Vecteurs neoantigeniques alphaviraux
EP4400174A2 (fr) 2017-09-01 2024-07-17 The Francis Crick Institute Limited Molecules immunoregulatrices et leurs utilisations
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
EP3735271A4 (fr) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. Anticorps anti-facteur tissulaire, conjugués anticorps-médicament et procédés associés
CN112384204B (zh) 2018-02-26 2023-03-14 安托瑞斯公司 致耐受性脂质体及其使用方法
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
JP2022534741A (ja) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2022032196A2 (fr) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Cassettes de vaccin à plusieurs épitopes
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0905253A3 (fr) * 1992-12-03 2000-11-02 Genzyme Corporation Vecteur adenovira délété de tous les ORF de E4 excepté ORF6
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ES2196018T3 (es) * 1993-08-11 2003-12-16 Wyeth Corp Vacunas de adenovirus recombinantes.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
CA2192442C (fr) * 1994-06-10 2007-09-25 Imre Kovesdi Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
WO1996009399A2 (fr) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Adenovirus chimerique permettant l'apport de genes
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors

Also Published As

Publication number Publication date
JP2001527420A (ja) 2001-12-25
CA2289611C (fr) 2009-11-03
DE69834489T2 (de) 2006-09-07
MXPA99010787A (es) 2005-12-12
WO1998053087A1 (fr) 1998-11-26
CA2289611A1 (fr) 1998-11-26
ATE325885T1 (de) 2006-06-15
BR9809846A (pt) 2000-06-20
EP0988389A1 (fr) 2000-03-29
HUP0003331A2 (hu) 2001-02-28
NZ500920A (en) 2001-04-27
EP0988389B1 (fr) 2006-05-10
HUP0003331A3 (en) 2003-01-28
DE69834489D1 (de) 2006-06-14
AU743923B2 (en) 2002-02-07
PL336941A1 (en) 2000-07-17
AU7584998A (en) 1998-12-11
SK156799A3 (en) 2000-05-16
US5849561A (en) 1998-12-15

Similar Documents

Publication Publication Date Title
IL133011A0 (en) Method for the production of non-group c adenoviral vectors
PL327984A1 (en) Complementary systems of adenoviral vectors and cell lines
BR9910251A (pt) Estimulação hematopoiética
AU7264694A (en) Defective adenovirus vectors and use thereof in gene therapy
WO2001031335A3 (fr) Procede de criblage des modulateurs de proliferation cellulaire et procedes de diagnostic d'etats de proliferation cellulaire
NZ334034A (en) Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype
DE69617583D1 (de) In vitrozellkultur-System
CA2146734A1 (fr) Methode pour la sous-culture a long terme de cellules de papilles dermiques
AU518774B2 (en) Changing rolling schedule in tandem rolling mill
AU2452197A (en) Genes amplified in cancer cells
WO2001004282A3 (fr) Vecteurs anti-cancereux de replication
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
TR199900799T2 (xx) Eterlipid/tamamlay�c� �ekillendirilmi� lipit kombinasyonu i�eren ta��y�c�lar.
ZA966803B (en) Cell culture products.
EP0960128A4 (fr) Produit genetique excedentaire dans les cellules cancereuses
GB2314332B (en) Gene expression in mammalian cells
IL97801A0 (en) Oligonucleotides,methods for in vitro tissue cell culture using the same and cosmetic compositions containing the same
AU7794700A (en) Recombinant adenoviruses preparation and adenovirus banks
IT8448170A0 (it) Perfezionamento nelle strutture disupporto di griglie di distribuzione,in particolare per recipienti di reazione ad alta pressione
WO1998020146A3 (fr) Expression genique transitoire stabilisee
AU5474899A (en) Genes amplified in cancer cells
Appleton Overlooking the obvious-technology and gender
CA2475337A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
Stone White House to take crack at reinventing science.
AR243231A1 (es) Procedimiento para producir medios de cultivo.